Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Therapeutic Monoclonal Antibodies Targeting Cytokine Storm: Inclusion as a Future Treatment for the Severe Cases of COVID-19
*Corresponding Author: Priti Mehta, Department of Pharmaceutical Analysis, Institute of Pharmacy, Nirma University, S.G. Highway, Ahmedabad, India, Email: drpritimehta@nirmauni.ac.in
Citation: Priti Mehta, Shikha Patel, Bhagawati Saxena (2021) Therapeutic Monoclonal Antibodies Targeting Cytokine Storm: Inclusion as a Future Treatment for the Severe Cases of COVID-19 .J Cytokine Biol 6: 048.
Copyright: © 2021 Mehta P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Clinical studies have manifested immunotherapeutics as the most propitious for the management of COVID-19 so far. However, the springing up variants of SARS CoV-2 has positioned the role of preventive immunotherapeuticsvaccines in doubt. Even so therapeutic monoclonal antibodies, Tocilizumab-an IL-6 inhibitor and Ravulizumab-a complement protein C5a blocker which are in clinical trial phase –IV are ascertained to be effectual for the COVID-19 cytokine storm and are envisioned to be included as an approved treatment for the severe COVID-19 cases.
